By proceeding, I agree that I understand the following disclosures:
I. How We Work in Washington. Based on your preferences, we provide you with information about one or more of our contracted senior living providers ("Participating Communities") and provide your Senior Living Care Information to Participating Communities. The Participating Communities may contact you directly regarding their services. APFM does not endorse or recommend any provider. It is your sole responsibility to select the appropriate care for yourself or your loved one. We work with both you and the Participating Communities in your search. We do not permit our Advisors to have an ownership interest in Participating Communities.
II. How We Are Paid. We do not charge you any fee – we are paid by the Participating Communities. Some Participating Communities pay us a percentage of the first month's standard rate for the rent and care services you select. We invoice these fees after the senior moves in.
III. When We Tour. APFM tours certain Participating Communities in Washington (typically more in metropolitan areas than in rural areas.) During the 12 month period prior to December 31, 2017, we toured 86.2% of Participating Communities with capacity for 20 or more residents.
IV. No Obligation or Commitment. You have no obligation to use or to continue to use our services. Because you pay no fee to us, you will never need to ask for a refund.
V. Complaints. Please contact our Family Feedback Line at (866) 584-7340 or
[email protected] to report any complaint. Consumers have many avenues to address a dispute with any referral service company, including the right to file a complaint with the Attorney General's office at: Consumer Protection Division, 800 5th Avenue, Ste. 2000, Seattle, 98104 or 800-551-4636.
VI. No Waiver of Your Rights. APFM does not (and may not) require or even ask consumers seeking senior housing or care services in Washington State to sign waivers of liability for losses of personal property or injury or to sign waivers of any rights established under law.I agree that: A.I authorize A Place For Mom ("APFM") to collect certain personal and contact detail information, as well as relevant health care information about me or from me about the senior family member or relative I am assisting ("Senior Living Care Information"). B.APFM may provide information to me electronically. My electronic signature on agreements and documents has the same effect as if I signed them in ink. C.APFM may send all communications to me electronically via e-mail or by access to an APFM web site. D.If I want a paper copy, I can print a copy of the Disclosures or download the Disclosures for my records. E.This E-Sign Acknowledgement and Authorization applies to these Disclosures and all future Disclosures related to APFM's services, unless I revoke my authorization. You may revoke this authorization in writing at any time (except where we have already disclosed information before receiving your revocation.) This authorization will expire after one year. F.You consent to APFM's reaching out to you using a phone system than can auto-dial numbers (we miss rotary phones, too!), but this consent is not required to use our service.
*If I am consenting on behalf of someone else, I have the proper authorization to do so. By clicking Get My Results, you agree to our
Privacy Policy. You also consent to receive calls and texts, which may be autodialed, from us and our customer communities. Your consent is not a condition to using our service. Please visit our
Terms of Use. for information about our privacy practices.
ST. PAUL, MN -- September 22, 1999 -- Patients with dementia face not only life-altering changes in mental abilities, but also changes in behavior that can lead to aggression and agitation. Kicking, swearing or biting, the violent behaviors associated with the late stages of dementia, may improve with a new medication, according to a study in the September 22 issue of Neurology, the scientific journal of the American Academy of Neurology.
Researchers suggest that risperidone can reduce the severity and frequency of aggressive and agitated behaviors in elderly people with dementia.
"It’s important for people, especially caregivers, to know that violent behaviors can be treated," said neurologist and study author Peter De Deyn, MD, of the University of Antwerp in Belgium. "Nearly 80 percent of people in the late stages of dementia develop violent behaviors.
Risperidone can improve the quality of life for these patients and their caregivers."
In a 13-week study of 223 people in seven European countries and Canada, researchers investigated risperidone as a treatment for the behavioral symptoms of dementia. Researchers compared the effects risperidone to the drug haloperidol (another medication used to treat aggressive symptoms of dementia) and a placebo in people with frequent aggressive behaviors associated with the late stages of dementia.
Study participants, an average age of 81, lived in nursing homes. Sixty-seven percent of people in the study had dementia related to Alzheimer’s disease, 26 percent had vascular dementia and the remaining patients had other types of dementia.
Researchers gave one-third of the study participants risperidone, one-third haloperidol and one-third a placebo. Each person’s health, severity of dementia and frequency of aggressive behaviors were evaluated prior to and during the study.
The severity of aggression was improved by two to four times more in people taking risperidone than those taking a placebo. The number of physical or verbally aggressive episodes improved by 34 percent for people taking risperidone as compared to 8 percent of people taking the placebo. "Our results suggest that risperidone caused not only an anti-psychotic effect, but also an anti-aggressive effect," said De Deyn.
People on haloperidol also showed an improvement in aggressive behaviors which was 20 percent greater than those taking the placebo. In comparing the two medications, risperidone had up to a 40 percent greater improvement on aggressive behaviors than haloperidol.
Researchers also suggest risperidone is more tolerable in elderly patients than haloperidol. "Haloperidol can cause some people to experience muscle stiffness and tremors similar to Parkinson’s disease," said De Deyn.
Medications causing drowsiness may appear to improve aggression. Researchers determined that haloperidol and risperidone caused some drowsiness, but overall it did not affect study results.
After the study was in progress, 121 people dropped out of the original study group of 344 people. The study was completed by 223 people. The most common reasons patients gave for dropping out of the study were side effects and lack of effectiveness. The dropouts came equally from the risperidone, haloperidol and placebo groups.
"A dementia patient’s violent behaviors may underlie a caregiver’s decision to place their loved one in a nursing home," said De Deyn. "As the world’s population ages, there may be more people with dementia. To manage the personal and societal costs associated with having more dementia patients in nursing homes, it’s essential that we find better ways to care for patients with dementia."
The American Academy of Neurology, an association of more than 16,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research.